Skip to main content

Correction to: Current outlook on radionuclide delivery systems: from design consideration to translation into clinics

Correction to: J Nanobiotechnol (2019) 17:90 https://doi.org/10.1186/s12951-019-0524-9

After publication of this article [1], an error was found in the description of the holmium isotopes. 165Ho is a stable isotope a fraction of which is activated to 166Ho by neutron activation in a nuclear reactor [2]. In one paragraph of the published article, describing holmium containing QuiremSpheres, 165Ho should be replaced with 166Ho. The correct description is given below:

“QuiremSpheres are poly-l-lactic acid based microspheres, containing 166Ho. The size of the particles varies from 15 to 60 μm and the use of poly-l-lactic acid allows to achieve the particle density of 1.4 g/cm3, which is closer to the density of blood (1.06 g/cm3). The 165Ho is activated to 166Ho with neutron activation in a nuclear reactor. Due to the short half-life period of 166Ho, each patient dose of QuiremSpheres needs to be prepared separately, thus, a specific activity can differ in each dose and depends on the needs of a patient.”

References

  1. 1.

    Peltek OO, Muslimov AR, Zyuzin MV, Timin AS. Current outlook on radionuclide delivery systems: from design consideration to translation into clinics. J Nanobiotechnol. 2019;17(1):90. https://doi.org/10.1186/s12951-019-0524-9.

    Article  Google Scholar 

  2. 2.

    Reinders MTM, Smits MLJ, van Roekel C, Braat AJAT. Holmium-166 microsphere radioembolization of hepatic malignancies. Semin Nucl Med. 2019;49(3):237–43. https://doi.org/10.1053/j.semnuclmed.2019.01.008.

    Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Alexander S. Timin.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the articleΓÇÖs Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the articleΓÇÖs Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Peltek, O.O., Muslimov, A.R., Zyuzin, M.V. et al. Correction to: Current outlook on radionuclide delivery systems: from design consideration to translation into clinics. J Nanobiotechnol 18, 2 (2020). https://doi.org/10.1186/s12951-019-0558-z

Download citation